<DOC>
	<DOCNO>NCT01028092</DOCNO>
	<brief_summary>This study design evaluate efficacity safety everolimus ( cyclosporine everolimus ) vs. cyclosporine immunosuppressive treatment renal transplantation elderly ( &gt; 60 year old ) recipients receive graft elderly donor ( &gt; 60 year old ) .</brief_summary>
	<brief_title>mTor-inhibitor ( EVERolimus ) Based Immunosuppressive Strategies CNI Minimisation OLD Old Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patient give write informed consent participate study First second single transplantation recipient ( male female ) old 60 year old Donor old 60 year old PRA &lt; 30 % Living donor Third transplantation PRA &gt; 30 % Other protocoldefined inclusion/exclusion criterion may apply . Recipient multiorgan transplant Active major infection ( HBV , HCV , HIV ) Loss first graft immunologic issue Anemia ( &lt; 9g/l ) leucopenia ( &lt; 2500/mm3 )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>